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Background: Women are disproportionately affected by cardiovascular disease, often experiencing poorer
outcomes following a cardiovascular event. Evidence points to inequities in processes of care as a potential
contributing factor. This study sought to determine whether any sex differences exist in adherence to process of
care guidelines for cardiovascular disease within primary care practices in Ontario, Canada.
Methods: This is a secondary analysis of pooled cross-sectional baseline data collected through a larger quality
improvement initiative known as the Improved Delivery of Cardiovascular Care (IDOCC). Chart abstraction was
performed for 4,931 patients from 84 primary care practices in Eastern Ontario who had, or were at high risk of,
cardiovascular disease. Measures examining adherence to guidelines associated with nine areas of cardiovascular
care (coronary artery disease, peripheral vascular disease (PVD), stroke/transient ischemic attack, chronic kidney
disease, diabetes, dyslipidemia, hypertension, smoking cessation, and weight management) were collected.
Multivariable logistic regression analysis was performed to evaluate sex differences, adjusting for age, physician
remuneration, and rurality.
Results: Women were significantly less likely to have their lipid profiles taken (OR = 1.17, 95% CI 1.03-1.33), be
prescribed lipid lowering medication for dyslipidemia (OR = 1.54, 95% CI 1.20-1.97), and to be prescribed ASA
following stroke (OR = 1.56, 95% CI 1.39-1.75). Women with PVD were significantly less likely to be prescribed ACE
inhibitors and/or angiotensin receptor blockers (OR = 1.74, 95% CI 1.25-2.41) and lipid lowering medications
(OR = 1.95, 95% CI 1.46-2.62) or ASA (OR = 1.59, 95% CI 1.43-1.78). However, women were more likely to have two
blood pressure measurements taken and to be referred to a dietician or weight loss program. Male patients with
diabetes were less likely to be prescribed glycemic control medication (OR = 0.84, 95% CI 0.74-0.86).
Conclusions: Sex disparities exist in the quality of cardiovascular care in Canadian primary care practices, which
tend to favour men. Women with PVD have a particularly high risk of not receiving appropriate medications. Our
findings indicate that improvements in care delivery should be made to address these issues, particularly with
regard to the prescribing of recommended medications for women, and preventive measures for men.
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The World Health Organization has made a specific call
for greater evaluation of the impact of health care reforms
on health equity within developed nations, thereby helping
ensure that individuals attain their optimum level of
health regardless of their ethnicity, age, gender, sexual
orientation, social class or other circumstances [1]. Over
the past decade, primary care has undergone significant
reform within Canada, as many provinces have instituted
novel physician funding approaches, team-based care
models, and placed a greater emphasis on the role of pri-
mary care in chronic disease management. Despite this
energetic reform, few studies have sought to examine
whether patients are receiving a comparable quality of
care across primary care practices, and if not, which
patient-level characteristics are associated with lower
quality care in order to address potential inequities.
A large body of literature suggests that women have
poorer cardiovascular disease outcomes as compared to
men [2]. While reasons for this disparity in cardiovascular
disease outcomes are contested [3], research points to in-
equities in the process of care as a possible contributing
factor. Some of these observed disparities may be
explained by recent realizations that a misinterpretation of
women’s CVD symptoms, or a lack of integration of
knowledge regarding female presentations into practice,
has frequently resulted in inadequate diagnoses and ma-
nagement in female patients [4]. One study has noted that
women in primary care settings with coronary heart
disease or congestive heart failure are less likely to receive
cardiology consultations than men, and that consultation
is associated with better processes of care, especially for
women [5]. A review of patients with diabetes in Sweden
reported women as having more frequent outpatient con-
tacts, less patient satisfaction, and a lower health-related
quality of life than men with diabetes [6]; however, no
gender differences were found in their levels of glycemic
control. Another recent study examining gender equity in
primary care practices by remuneration structure found
that women attending fee-for-service practices were
significantly less likely to have received recommended care
for chronic diseases, a difference not observed in capita-
tion-based practices [7].
This study sought to determine whether patient sex
differences exist in relation to adherence to process of
care guidelines for cardiovascular disease within primary
care practices in Ontario, with the goal of identifying
specific gaps for improvement of equity in care delivered
within the primary care system.
Methods
IDOCC study design
The project involves a secondary analysis of pooled cross-
sectional baseline data collected through a larger qualityimprovement initiative known as the Improved Delivery
of Cardiovascular Care (IDOCC) study [8]. IDOCC used
trained facilitators to work with primary care providers
within 84 primary care practices across eastern Ontario
over a 24-month period, in order to help them incorporate
elements of the Chronic Care Model into daily care rou-
tines for both male and female patients. Levels of ad-
herence to CVD guidelines following this intervention
were evaluated in a cluster randomized controlled trial.
Baseline medical data were collected from 4,931 patients,
who either have or are at high risk for developing car-
diovascular disease, to study adherence rates to recom-
mended guidelines for CVD care. The data for this study
are drawn from the baseline chart abstraction, and repre-
sent patient-level guideline adherence rates prior to inter-
vention. Further details regarding the study protocol have
been published elsewhere [8]. This project has received
ethical approval from the Ottawa Hospital Research Ethics
Board (2007292-01H).
Adherence to cardiovascular disease care guidelines
Data on guideline adherence were collected across nine
areas of care related to CVD care: coronary artery disease,
peripheral vascular disease, stroke/transient ischemic at-
tack, chronic kidney disease, diabetes, dyslipidemia, hyper-
tension, smoking cessation care, and weight management.
The Champlain Primary Care CVD Prevention and Ma-
nagement Guideline (www.idocc.ca) was developed based
on the recommendations of seven Evidence Monitoring
Committees [9]. Included guidelines yielded a compre-
hensive list of process of care measures associated with
screening, drug prescriptions, counselling and referral to
external programs. Our main outcomes were dichotom-
ous indicators of process of care measures appropriate to
each of the nine areas (e.g., whether a lipid profile was
Table 2 Frequency of adherence to process of care guidelines in treatment of study participants
Percentage of patients receiving care
Care indicator All Males Females
All (n = 4931) 4931 (100%) 2411 (48.9%) 2520 (51.1%)
Lipid profile 3968 (78.9%) 1977 (80.3%) 1991 (77.4%)
Waist circumference 518 (10.3%) 279 (11.3%) 239 (9.3%)
Dietician/weight loss program referral 931 (18.5%) 449 (18.2%) 482 (18.8%)
Smoking status recorded 4805 (95.5%) 2346 (95.4%) 2459 (95.7%)
2 Blood pressure measures 3745 (74.1%) 1778 (72.2%) 1967 (76.5%)
High-Risk for CVD (n = 1143) 1143 (100%) 507 (44.4%) 636 (55.6%)
Lipid profile 904 (79.1%) 408 (80.5%) 496 (78.0%)
Waist circumference measure 85 (7.4%) 49 (9.7%) 36 (5.7%)
Dietician/weight loss program referral 142 (12.4%) 60 (11.8%) 82 (12.9%)
Smoking status recorded 1109 (97.0%) 487 (96.0%) 622 (97.8%)
2 Blood pressure measures 811 (100%) 351 (69.2%) 460 (72.3%)
Coronary Artery Disease (n = 1502) 1502 (100%) 931 (62.0%) 571 (22.4%)
Fasting blood glucose 1197 (79.7%) 749 (80.5%) 448 (78.5%)
Medication (ACE, Angiotensin receptor blocker, beta blocker) 1339 (89.2%) 830 (89.2%) 509 (89.2%)
ASA 1156 (77.0%) 725 (77.8%) 431 (75.5%)
Peripheral Vascular Disease (n = 311) 311 (100%) 191 (61.4%) 120 (38.6%)
Fasting blood glucose 244 (78.5%) 154 (80.6%) 90 (75.0%)
ACE inhibitor and/or Angiotensin receptor blocker 182 (58.5%) 110 (57.6%) 72 (60.0%)
Lipid lowering medication 232 (74.6%) 147 (76.9%) 85 (70.8%)
ASA 238 (76.5%) 147 (77.0%) 91 (75.8%)
Stroke (n = 627) 627 (100%) 293 (46.7%) 334 (53.3%)
Fasting blood glucose 474 (76.6%) 225 (77.8%) 249 (75.5%)
ASA 493 (79.6%) 231 (79.9%) 262 (79.4%)
If stroke within past year (n = 69) 69 (100%) 32 (48.4%) 37 (53.6%)
Echo cardiogram 36 (52.2%) 15 (46.9%) 21 (56.8%)
Carotid doppler 46 (66.7%) 20 (62.5%) 26 (70.3%)
CT head scan 51 (73.4%) 24 (75.0%) 27 (73.0%)
EKG 38 (55.1%) 17 (53.1%) 21 (56.8%)
Diabetes (n = 2343) 2343 (100%) 1111 (47.4%) 1232 (52.6%)
Two HbA1c tests 1275 (54.4%) 622 (56.0%) 653 (53.0%)
Glycemic control medication 1882 (80.3%) 896 (80.7%) 986 (80.0%)
ACR 1327 (56.1%) 655 (58.5%) 672 (54.0%)
eGFR 1959 (83.6%) 934 (84.1%) 1025 (83.2%)
Chronic Kidney Disease (n = 923) 923 (100%) 406 (44.0%) 517 (56.0%)
ACR 488 (52.9%) 233 (57.4%) 255 (49.3%)
Dyslipidemia† (n = 4207) 4207 (100%) 2124 (50.5%) 2083 (49.5%)
Lipid profile 3534 (83.2%) 1799 (83.8%) 1735 (82.6%)
Lipid lowering medication 3879 (91.4%) 1993 (92.9%) 1886 (89.8%)
Hypertension‡ (n = 3857) 3857 (100%) 1827 (47.4%) 2030 (52.6%)
Two blood pressure readings 3083 (79.2%) 1407 (77.1%) 1649 (81.2%)
Anti-Hypertensive medication 3627 (94.0%) 1713 (93.8%) 1914 (94.3%)
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Table 2 Frequency of adherence to process of care guidelines in treatment of study participants (Continued)
Smoking (n = 1076) 1076 (100%) 557 (51.8%) 519 (48.2%)
Smoking cessation counselling 567 (52.7%) 294 (52.8%) 273 (52.6%)
Smoking cessation program 86 (8.0%) 46 (8.3%) 40 (7.7%)
Smoking cessation drug 249 (23.0%) 128 (23.0%) 121 (23.3%)
†Dyslipidemia defined as low-density lipoprotein (LDL) >2.0 mmol/L.
‡Hypertension defined as >130/80 mmHg for patients with diabetes or CKD; >140/90 mmHg for everyone else.
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ral to smoking cessation program), over the course of
12 months.
In addition to those patients diagnosed with one of the
above conditions, a group at high-risk for cardiovascular
disease was also identified. This group was identified based
on the presence of at least three of the following risk fac-
tors: age (males ≥ 45, females ≥55), smoker, hypertension,
and dyslipidemia [8]. Hypertension was defined as >130/
80 mmHg for patients with diabetes or CKD and >140/
90 mmHg for everyone else, and dyslipidemia was defined
as low-density lipoprotein (LDL) >2.0 mmol/L.Statistical analysis
Patient- and practice-level descriptive statistics were gener-
ated for key characteristics of our sample. Baseline rates of
adherence to each process of care indicator were computed
for males and females. Logistic regression analysis was con-
ducted to evaluate differences in guideline adherence for
male and female patients. The method of Generalized
Estimating Equations (GEE) was used to account for clus-
tering of patients within practices. The dependent variable
was a dichotomous indicator of adherence to each process
of care measure. The main predictor variable was patient
sex. We adjusted for practice structure, rurality, and pa-
tient age as covariates, because these have been suggested
in the literature as being important predictors of quality of
care [10,11]. Separate analyses were performed for patients
with established disease and patients in the high-risk
group. All analyses were performed using SAS 9.2 (SAS
Institute Incorporated, Cary, North Carolina, USA).Results
Of the 4,931 patients in our sample, 48.9% were male and
51.1% were female (Table 1). The mean age was 66 years.
Of these, 1,502 participants were diagnosed with CAD and
311 with PVD (Table 2). A total of 627 patients had suf-
fered from a stroke, 69 of whom had experienced one
within the previous year. A large number of patients had
diabetes (2,343), chronic kidney disease (923), dyslipidemia
(4,207) and/or hypertension (3,857). Over 20% (1,076) of
the sample were current smokers. In addition to patients
with established disease, 1,143 patients (23.2%) were iden-
tified as being at high risk for cardiovascular disease.Of the 84 participating practices, approximately half
(52.4%) had a fee for service remuneration structure, one
third (32.9%) had a capitation-based structure, and 14.6%
were salary-based community health centres (Table 1).
The majority of these practices (82.1%) were located in
urban areas.
Overall, women were significantly less likely to have their
lipid profiles taken (OR = 1.17 [95% CI, 1.03-1.33]), be pre-
scribed lipid lowering medication for their dyslipidemia
(OR = 1.54 [95% CI, 1.20-1.97]), or to be prescribed ASA
following stroke (OR = 1.56 [95% CI, 1.39-1.75]) than men
(Table 3). In particular, women with PVD were significantly
less likely to be prescribed ACE inhibitors and/or angioten-
sin receptor blockers (OR = 1.74 [95% CI, 1.25-2.41]), lipid
lowering medications (OR = 1.95 [95% CI, 1.46-2.62]) or
ASA (OR = 1.59 [95% CI, 1.43-1.78]). However, they were
generally more likely to have two blood pressure measure-
ments than men (OR = 0.83 [95% CI, 0.71-0.96]) and to be
referred to either a dietician or weight loss program
(OR = 0.87 [95% CI, 0.76-0.98]). Conversely, male patients
with diabetes were less likely to be prescribed glycemic
control medication than women (OR = 0.84 [95% CI,
1.43-1.78]), and hypertensive men were less likely to have
two blood pressure readings taken (OR = 0.79 [95% CI,
0.66-0.94]). It is also worth noting that the odds ratios
observed were higher than expected from the raw data
following adjustment for age, which was a highly significant
covariate across most of the models, with an observed
effect in the direction opposite to that of patient sex.
No statistically significant differences in delivery of care
by sex were observed in patients with coronary artery dis-
ease and chronic kidney disease. Male and female patients
who smoked were equally likely to receive referrals for
smoking cessation counselling or programs, and to be
prescribed smoking cessation medications (Table 3). In
addition, no differences in adherence to overall care guide-
lines were observed between sexes in the group identified
as high-risk for cardiovascular disease (Table 4).
Discussion
The overall results of this study reveal some important sex
differences in the adherence to cardiovascular disease care
guidelines in primary care practices in Eastern Ontario,
notably with respect to medication use and preventive
measures. The main trends we observed included lower
Table 3 Adjusted odds ratios comparing adherence to care guidelines for female versus male patients†
Care indicator OR 95% CI P-value
All (n = 4931)
Lipid profile not taken 1.17 [1.03-1.33] 0.01*
Waist circumference not measured 1.17 [0.93-1.47] 0.17
Dietician/weight loss program - no referral 0.87 [0.76-0.98] 0.04*
Smoking status not recorded 1.08 [0.84-1.39] 0.54
2 Blood pressure measures not taken 0.83 [0.71-0.96] 0.01*
Coronary Artery Disease (n = 1502)
Fasting blood glucose not taken 1.08 [0.82-1.42] 0.56
No medication prescribed (ACE, Angiotensin receptor blocker, beta blocker) 1.07 [0.74-1.55] 0.72
ASA not prescribed 1.13 [0.86-1.49] 0.37
Peripheral Vascular Disease (n = 311)
Fasting blood glucose not checked 1.00 [0.88-1.14] 0.98
ACE inhibitor and/or Angiotensin receptor blocker not prescribed 1.74 [1.25-2.41] <0.01**
Lipid lowering medication not prescribed 1.95 [1.46-2.62] <0.01**
ASA not prescribed 1.59 [1.43-1.78] <0.01**
Stroke (n = 627)
Fasting blood glucose not checked 1.00 [0.88-1.14] 0.98
ASA not prescribed 1.56 [1.39-1.75] <0.01**
If stroke within past year (n = 69)
Echo cardiogram not recommended 0.74 [0.29-1.91] 0.53
Carotid Doppler not recommended 0.56 [0.82-2.31] 0.42
CT head scan not recommended 1.39 [0.37-5.23] 0.63
EKG not recommended 0.59 [0.16-2.12] 0.42
Diabetes (n = 2343)
Two HbA1c tests not recommended 0.93 [0.81-1.07] 0.33
Glycemic control medication not prescribed 0.84 [0.74-0.96] <0.01**
ACR test not recommended 0.93 [0.82-1.05] 0.22
eGFR test not recommended 1.00 [0.90-1.12] 0.96
Chronic Kidney Disease (n = 923)
ACR test not recommended 0.93 [0.82-1.04] 0.20
Dyslipidemia (n = 4207)
Lipid profile not taken 1.09 [0.94-1.27] 0.23
Lipid lowering medication not prescribed 1.54 [1.20-1.97] <0.01**
Hypertension (n = 3857)
2 Blood pressure measured not taken 0.79 [0.66-0.94] 0.01*
Anti-Hypertensive medication not prescribed 1.09 [0.86-1.38] 0.48
Smoking (n = 1076)
Smoking cessation counselling - no referral 0.94 [0.74-1.20] 0.63
Smoking cessation program - no referral 0.94 [0.61-1.47] 0.80
Smoking cessation drug - not prescribed 0.94 [0.72-1.23] 0.68
†Adjusted for patient age, practice fee structure and rurality.
*Significant at p = 0.05 level, **p = 0.01 level.
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Table 4 Adjusted odds ratios comparing adherence to
CVD care guidelines in high risk group (n = 1143)†
Care indicator OR 95% CI P-value
Lipid profile not taken 1.11 [0.85 – 1.46] 0.45
Waist circumference not measured 1.39 [0.77 – 2.50] 0.28
Dietician/weight loss program – no referral 0.78 [0.69 – 1.13] 0.19
Smoking status not recorded 0.52 [0.22 – 1.24] 0.14
2 Blood pressure measures not taken 0.92 [0.69 – 1.21] 0.55
†Adjusted for patient age, practice fee structure and rurality.
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mended for women; much lower rates of guideline adhe-
rence specific to peripheral vascular disease in women;
unequal rates of overall medication prescription (e.g.,
ASA, lipid-lowering medication, and glycemic control
medication) between sexes; and lower rates of screening
or preventive procedures (e.g., dietician/weight loss pro-
gram referral, and blood pressure measurement) in men.
While overall, women were less likely to have their lipid
profiles taken, men and women with a confirmed diagno-
sis of dyslipidemia were equally likely to have these taken.
This implies that while screening tests for dyslipidemia
are less likely to be ordered for women, no differences in
relation to lipid monitoring tests in those patients known
to have dyslipidemia are apparent. However, within this
group, women were still less likely to receive a lipid lowe-
ring medication for their condition. These findings point
to two distinct gaps in lipid-related care for women in this
sample - the first relating to detection, and the second
relating to treatment by recommended medications. The
latter finding is supported by several recent studies, one of
which demonstrated that although total measured choles-
terol levels were higher in women with diabetes (n = 835),
women with diabetes had lower prescription rates of hy-
polipidaemic medications compared with men of a similar
age [12]. Another study of arterial disease reports that
women are significantly less likely than men to receive
lipid-lowering agents than men, although no differences
were observed in primary outcomes (e.g., cardiovascular
death, MI or stroke) between the sexes [13]. A recent trial
found that the degree of risk reduction associated with
statin therapy following myocardial infarction is less in
women than in men [14].
The most striking disease-specific results we observed
were in relation to peripheral vascular disease. Women
with this diagnosis were much less likely to receive any of
the recommended medications for their condition (ASA,
ACE inhibitors and/or angiotensin receptor blockers or
lipid lowering medications) compared to men. These ob-
served prescribing practices are also supported by a study
in Swedish primary care facilities, which shows that men
with PVD have higher odds of being prescribed a lipid-
lowering therapy (OR = 1.3; 95% CI: 1.1-1.5), ACEinhibitors or beta blockers (OR = 1.3; 95% CI: 1.0-1.7), or
antiplatelet therapy (OR = 1.5; 95% CI: 1.2-1.9) than
women [15]. These trends are also reflected by much ear-
lier research (circa the late 1980′s), which documented
the age-adjusted likelihood of having a procedure related
to PVD as being 1.7 times higher in men than women
[16]. Together, these findings indicate that potentially little
has changed in terms of inequities in the process of care
for women with PVD in primary care settings over the last
20 years. Notably, the American Heart Association has
recently issued a “call to action” for the improvement of
PVD care in women, observing that research in women
with this disease has lagged far behind that relating to
men [17]. This is concerning given the severe conse-
quences of untreated PVD, which include heart attack,
stroke, limb disability or amputation [18]. The longer-
term consequences of PVD may result in a dispropor-
tionate burden of disease in women if a lack of treatment
leads to higher levels of complications and disease seve-
rity; indeed, a recent study found that after 4 years of
follow-up, women with PVD have much greater mobility
loss and faster functional decline than men [19], a finding
which could be explained by process of care patterns ob-
served here.
As mentioned above, these observed trends can also be
attributed to a propensity to under-prescribe specific types
of medications according to sex. We documented the
under-prescribing of ASA, lipid lowering medications and
ACE inhibitors and/or angiotensin receptor blockers to
women with stroke, PVD and dyslipidemia. These findings
are supported by those from a large recent study in a
Finnish population, which demonstrated that younger
women with a prior CVD event had a lower rate of ASA
usage than men (although no gender differences were seen
in the use of other preventive medication usage) [20]. In
addition, a study using the EUROASPIRE III data showed
that while statins and beta-blockers were equally pre-
scribed to men and women, antiplatelet agents (e.g., ASA)
were used less in women [12]. Notably, women in the
EUROASPIRE III study were less likely to achieve their
treatment goals [12].
Not all of the observed disparities in measures of care
favoured men; indeed, men were less likely to be referred
to weight loss programs or dieticians, as well as to have
two blood pressure measures taken as per recommenda-
tions. The increased rates of referral to these programs for
women might indicate a perception on the part of the
physician that women are more likely to comply with such
interventions. This is supported by findings on physician
attitudes towards weight loss and gender, which found
that in slightly overweight patients (BMI = 25 kg/m2), fe-
male patients are much more likely to be recommended
to lose weight than male patients [21]. Interestingly, these
researchers observed a reversal of this trend at higher
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strongly encouraged to lose weight than similarly obese
female patients [21]. Together with our findings, this indi-
cates that although men overall may be less encouraged to
lose weight, those at the highest risk for weight-related
complications are still more likely than women to receive
the appropriate care for this condition. A potentially con-
cerning finding for men with diabetes in our sample was
their reduced likelihood of receiving glycemic control
medication as compared to women.
Interestingly, no sex differences were observed in guide-
line adherence for patients within the high cardiovascular
disease risk group. This implies that processes of care for
early detection and prevention of CVD are delivered
equally regardless of sex within the practices in our sam-
ple. This finding is a positive one, especially in light of the
literature regarding sex differences in screening for CVD
within high-risk populations.Limitations
The clinicians participating in the IDOCC initiative did so
voluntarily, and the data collected may therefore be sub-
ject to a degree of selection bias. Notably, participating
practices may represent those who are generally higher
performing and may be more motivated to adhere to qua-
lity or process of care recommendations. However, this se-
lection bias is not expected to differ substantially with
respect to male or female patients, and the internal vali-
dity of the comparisons should therefore not be affected.
In addition, as with any study relying on chart audits for
data collection, we were only able to capture activities
which were reported in the patient file - those performed
but not recorded would not have been included in our
analysis. Similarly, we are unable to determine from this
data whether the care indicators in question were offered
to but refused by the patient, as the chart data only indi-
cated whether they were ultimately performed.Conclusions
In conclusion, these findings highlight some important
gaps in the quality of cardiovascular disease care in pri-
mary care practices, with implications for both women
and men. We found areas of care in which no sex dif-
ferences were observed, areas in which men fared worse
than women, and areas in which women fared worse than
men. The frequency and magnitude of these findings were
larger with respect to inadequacies in care in women, and
occurred in areas in which lack of appropriate care will
lead to more severe outcomes such as peripheral vascular
disease. Our findings indicate that improvements in care
delivery should be made to address these issues, particu-
larly with regard to the prescribing of recommended me-
dications for women, and preventive measures for men.Abbreviations
ACE: Angiotensin converting enzyme; ASA: Acetylsalicylic acid; BMI: Body
mass index; CI: Confidence interval; GEE: Generalized estimating equation;
IDOCC: Improved delivery of cardiovascular care; OR: Odds ratio.
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